Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Tolerability of TAK-881 in PIDD
NCT06076642Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Nov 2024
- Primary completion
- May 2028
- Modality
- SC (Subcutaneous administration)
- Countries
- 7
01
Overview
A Phase 3 trial of TAK-881 in primary immunodeficiency disease (PID), sponsored by Takeda. Started Nov 2024; status: active, not recruiting.
02
Drugs
TAK-881
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT06076642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06076642.